Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Our Medicine
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Calendar Events
      • Corporate Presentations
      • Scientific Publications
    • Corporate Governance
      • Committees and Governance Documents
      • Board of Directors
      • Leadership Team
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Contact
    Top Links
    • News & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
      • Grants & Funding
      • Investigator Sponsored Studies
      • Compliance Declaration
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Menin Inhibition
      • Farnesyl Transferase Inhibitors
      • Posters and Presentations
      • Scientific Manuscripts
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Our Medicine
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
        • Calendar Events
        • Corporate Presentations
        • Scientific Publications
      • Corporate Governance
        • Committees and Governance Documents
        • Board of Directors
        • Leadership Team
      • Financial Information
      • Analyst Coverage
      • FAQs
      • Contact
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Contact
    • MenuMenu

    SEC Filing Details

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Document Details

    Form
    144
    Filing Date
    05-20-2024
    Document Date
    05-20-2024
    Form Description
    Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
    Filing Group
    Other
    Company
    Kura Oncology, Inc.
    Issuer
    Kura Oncology, Inc.

    Filing Formats

    View HTML
    Download PDF
    Download DOC

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    • Our Medicine
    Footer Links - Investors New
    • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    Footer Links - News & Media
    • News & Media
    • Press Releases
    • News & Perspecitives
    • Expert Perspectives
    • Media Resources
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc. 
    4930 Directors Place, Suite 500 
    San Diego, CA 92121 
    (858) 500-8800

    Kura Oncology, Inc. 
    2 Seaport Lane, Suite 8A 
    Boston, MA 02210 
    (617) 588-3755

    © 2026 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy| Cookie Policy| Consumer Health Data

    Scroll to top